Summary
This prediction ended on 22.09.17 with a price of €16.78. klostergang's SELL prediction for Versartis closed completely unchanged. klostergang has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Versartis | - | - | - | - |
| iShares Core DAX® | 1,72 % | 3,37 % | 5,89 % | 52,38 % |
| iShares Nasdaq 100 | -4,56 % | -4,24 % | 21,39 % | 72,45 % |
| iShares Nikkei 225® | -7,12 % | -11,87 % | 42,36 % | 57,58 % |
| iShares S&P 500 | -0,89 % | 1,69 % | 19,49 % | 62,15 % |
Comments by klostergang for this prediction
In the thread Versartis diskutieren
Versartis' lead candidate VRS-317 flunks late-stage study
Thinly traded small cap Versartis (NASDAQ:VSAR) is set for a tumble after reporting negative results in a Phase 3 clinical trial, VELOCITY, assessing lead candidate somavaratan (VRS-317) for the treatment of pediatric growth hormone deficiency.